Posts tagged Oppenheimer


Is New Teva Pharmaceutical Industries Ltd (ADR) (TEVA) CEO Walking into a Landmine? Oppenheimer and Maxim Weigh In

Here’s why analysts are playing it cautiously optimistic on the struggling pharmaceutical giant.

Read more

Oppenheimer Sees Himax Technologies, Inc. (ADR) (HIMX) as an Overvalued Stock with Lost Growth Potential

Analyst warns that investors betting on Himax are naïve to bearish risks circling overhead.

Read more

DJI’s Spark Short Circuits Ambarella Inc (AMBA) Drone Revenue Leading to Weaker Outlook

Ambarella’s computer vision chips present enticing long-term possibilities, says Oppenheimer.

Read more

Palo Alto Networks Inc (PANW) New Product Development a Key to Continued Growth: Oppenheimer

Sales reorganization initiatives and improved execution levels are encouraging, says analyst.

Read more

Nutanix Inc (NTNX) Sharpens HCI Leadership Position Even as Competition Grows: Oppenheimer

Nutanix posts record high 45% rise in software sales.

Read more

Box Inc (BOX) Impresses Oppenheimer Following FQ2 Results Despite Backtrack to Negative Free Cash Flow

Analyst Expects More Upside Later in Fiscal 2018 and Fiscal 2019

Read more

Oppenheimer Comments on The Medicines Company (MDCO) Following FDA Approval for VABOMERE

The Medicines Company’s Vabomere – A Solid Option for CarbapenemResistant cUTIs: Oppenheimer

Read more

The Medicines Company (MDCO): Inclisiran Shows Momentum on Longer-Term Data, Oppenheimer Weighs in

Yesterday, at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, The Medicines Company …

Read more

Fitbit Inc (FIT) Shares Could Re-Rate Higher on Back of Digital Health Transformation: Oppenheimer

Focusing on DIY Fitness Crowd Is a Good Start, Says Analyst

Read more

Alibaba Group Holding Ltd (BABA) Gets Price Target Lift Following Stellar FQ1 Beat

On the heels of a solid fiscal first quarter beat from Alibaba Group Holding Ltd …

Read more